We are live on ! Find out more
ANIK icon

Anika Therapeutics
ANIK

157 hedge funds and large institutions have $403M invested in Anika Therapeutics in 2019 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 75 increasing their positions, 34 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

121% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 34

3.92% more ownership

Funds ownership: 89.83% → 93.75% (+3.9%)

3% less funds holding

Funds holding: 162 → 157 (-5)

6% less capital invested

Capital invested by funds: $429M → $403M (-$25.6M)

14% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 22

43% less call options, than puts

Call options by funds: $6.65M | Put options by funds: $11.6M

Holders
157
Holders Change
-5
Holders Change %
-3.09%
% of All Funds
3.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
75
Reduced
34
Closed
22
Calls
$6.65M
Puts
$11.6M
Net Calls
-$4.99M
Net Calls Change
-$4.69M

Top Buyers

1
Ameriprise
Ameriprise
Minnesota
+$15M
2
State Street
State Street
Massachusetts
+$7.72M
3
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management
California
+$5.98M
4
Baird Financial Group
Baird Financial Group
Wisconsin
+$5.44M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$5.14M

Top Sellers

1
First Manhattan
First Manhattan
New York
-$13.8M
2
EC
Engaged Capital
California
-$12.6M
3
AAM
AMI Asset Management
California
-$10.8M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$4.5M
5
PCM
Portolan Capital Management
Massachusetts
-$3.56M
Name Holding Trade Value Shares
Change 		Change in
Stake
HNB
151
Huntington National Bank
Ohio
$3K -$34 -1 -1%
CAM
152
Cresset Asset Management
Illinois
$1K +$171 +5 +21%
MAM
153
Meeder Asset Management
Ohio
$1K +$1.47K +43 New
GT
154
Glenmede Trust
Pennsylvania
$9 -$13.9K -405 -54%
First Manhattan
155
First Manhattan
New York
– -$13.8M -409,852 Closed
EC
156
Engaged Capital
California
– -$12.6M -374,926 Closed
AAM
157
AMI Asset Management
California
– -$10.8M -322,062 Closed
Wellington Management Group
158
Wellington Management Group
Massachusetts
– -$4.5M -133,894 Closed
RHJA
159
Rice Hall James & Associates
California
– -$1.61M -47,987 Closed
OTPPB
160
Ontario Teachers' Pension Plan Board
Ontario, Canada
– -$1.04M -30,998 Closed
AIMCA
161
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
– -$713K -21,200 Closed
SCA
162
Secor Capital Advisors
New York
– -$691K -20,574 Closed
Canada Life
163
Canada Life
Manitoba, Canada
– -$594K -19,150 Closed
AIM
164
Alambic Investment Management
California
– -$624K -18,559 Closed
GCP
165
GSA Capital Partners
United Kingdom
– -$457K -13,598 Closed
PP
166
Paloma Partners
Connecticut
– -$276K -8,200 Closed
Janus Henderson Group
167
Janus Henderson Group
United Kingdom
– -$264K -7,858 Closed
Susquehanna International Group
168
Susquehanna International Group
Pennsylvania
– -$259K -7,554 Closed
SRAM
169
Stone Ridge Asset Management
New York
– -$248K -7,378 Closed
William Blair & Company
170
William Blair & Company
Illinois
– -$240K -7,154 Closed
PTC
171
Petrus Trust Company
Texas
– -$200K -5,955 Closed
PCM
172
Prelude Capital Management
New York
– -$164K -4,865 Closed
Macquarie Group
173
Macquarie Group
Australia
– -$20K -600 Closed
TRCT
174
Tower Research Capital (TRC)
New York
– -$7K -204 Closed
PFBT
175
Parkside Financial Bank & Trust
Missouri
– -$1K -18 Closed
3 4 5 6
7

ANIK Hedge Fund Activity: Q1 2019 in Review

157 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q1 2019, worth a combined $403M — down 6% from $429M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of ANIK and 19 opened new positions — a net loss of 3 holders — while 34 trimmed existing stakes and 75 added.

The largest buyer was Ameriprise, adding an estimated $15M. The largest seller was First Manhattan, exiting entirely with an estimated $13.8M sold.

  • 157 institutional investors held Anika Therapeutics (ANIK) as of Q1 2019, down from 162 in Q4 2018.
  • Funds reported $403M of Anika Therapeutics stock for Q1 2019, down 6% quarter-over-quarter.
  • 19 funds opened new Anika Therapeutics positions in Q1 2019 and 22 closed out, a net change of -3 holders.
  • The largest Anika Therapeutics buyer in Q1 2019 was Ameriprise, an estimated $15M added.
  • The largest Anika Therapeutics seller in Q1 2019 was First Manhattan, an estimated $13.8M sold.

Based on aggregated 13F filings for Q1 2019.